The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
WCLC 2021 | The challenges of treating METex14 NSCLC
Paul Paik, MD, Memorial Sloan Kettering Cancer Center, New York, NY, discusses the treatment of patients with MET exon 14 skipping (METex14) non-small cell lung cancer (NSCLC) at WCLC 2021. Dr Paik outlines how the lack of prospective data from METex14 NSCLS patients, due to the need for identification of this mutation by next-generation sequencing, a relatively novel tool, poses challenges for identifying optimal treatment regimens. Dr Paik also identifies that METex14 NSCLC patients tend to be older than other NSCLC patients, and thus this cohort is often not reflected in randomized trials. This interview took place during the IASLC World Conference on Lung Cancer (WCLC) virtual meeting 2021.
